Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer
Condition(s):Non Squamous, Non-small-cell Lung CancerLast Updated:April 6, 2021Terminated
Hide Studies Not Open or Pending
Condition(s):Non Squamous, Non-small-cell Lung CancerLast Updated:April 6, 2021Terminated
Condition(s):Non-Small-Cell Lung CarcinomaLast Updated:March 5, 2015Completed
Condition(s):Advanced NSCLC Patients With T790MLast Updated:January 6, 2020Unknown status
Condition(s):NRG1-fused Non-small Cell Lung CancerLast Updated:April 1, 2021Unknown status
Condition(s):Locally Advanced Non-small Cell Lung CancerLast Updated:November 6, 2019Unknown status
Condition(s):Non-small Cell Lung CancerLast Updated:August 2, 2011Unknown status
Condition(s):Non-small Cell Lung Cancer Stage IIIB/IVLast Updated:March 15, 2024Recruiting
Condition(s):Locally Advanced Non-Small Cell Lung CancerLast Updated:May 22, 2014Terminated
Condition(s):Locally Advanced Non-Small Cell Lung Cancer; NSCLCLast Updated:July 15, 2013Completed
Condition(s):Non-small Cell Lung CancerLast Updated:June 9, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.